Advanced search
Publication Cover
The World Journal of Biological Psychiatry Volume 15, 2014 - Issue 6
Submit an article Journal homepage
733
Views
11
CrossRef citations to date
0
Altmetric
Research Article

A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in Japan

Nagahide TakahashiClinical Responsible Physician Department, Clinical Science Division, Janssen Pharmaceutical K.K, Tokyo, JapanCorrespondence[email protected]
,
Tadaishi KohClinical Science Initiative Department, Clinical Science Division, Pharmaceutical K.K, Tokyo, Japan
,
Yushin TominagaProject Lead Department, Project Development Division, Pharmaceutical K.K, Tokyo, Japan
,
Yuki SaitoBiostatistics Department, Quantitavie Science Division, Pharmaceutical K.K, Tokyo, Japan
,
Yuji KashimotoTrial Management Department, Japan Clinical Operations Division, Pharmaceutical K.K, Tokyo, Japan
&
Taka MatsumuraClinical Science Division, Pharmaceutical K.K, Tokyo, Japan
Pages 488-498 | Received 10 May 2013, Accepted 18 Nov 2013, Published online: 23 Jan 2014

References

  • American Psychiatric Association. 2000. Attention-deficit and disruptive behavior disorders. In: Diagnostic and statistical manual of mental disorders. 4th ed. text revision (DSM-IV-TR). Washington, DC: American Psychiatric Association. p 85–93.
  • Asherson P, Chen W, Craddock B, Taylor E. 2007. Adult attention-deficit hyperactivity disorder: recognition and treatment in general adult psychiatry. Br J Psychiatry 190:4–5.
  • Baron DA, Pato MT, Cyr RL. 2011. Treatment of adults with attention-deficit/hyperactivity disorder. J Am Osteopath Assoc 111:610–614.
  • Biederman J, Mick EO, Surman C, Doyle R, Hammerness P, Michel E, et al. 2007. Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. BMC Psychiatry 7:49.
  • Buitelaar JK, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemela A, Konofal E, et al. 2009. Safety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat 5:457–466. Epub@2009 Sep 15:457–466.
  • Buitelaar JK, Trott GE, Hofecker M, Waechter S, Berwaerts J, Dejonkheere J, et al. 2011. Long-term efficacy and safety outcomes with OROS-MPH in adults with ADHD. Int J Neuropsychopharmacol 15:1–13.
  • Concerta [package insert]. Tokyo: Janssen Pharmaceutical KK; 2007.
  • Conners CK, Erhardt D, Sparrow E. 1999. Conners’ Adult ADHD Rating Scales (CAARS): Technical Manual. NY: Multi-Health Systems Inc.
  • Epstein JN, Kollins SH. 2006. Psychometric properties of an adult ADHD diagnostic interview. J Atten Disord 9:504–514.
  • Johnson & Johnson Pharmaceutical Research & Development. 2011. Investigator's Brochure, CONCERTA® (methylphenidate HCl). Edition 16.
  • Kooij JJ, Buitelaar JK, van den Oord EJ, Furer JW, Rijnders CA, Hodiamont PP. 2005. Internal and external validity of attention-deficit hyperactivity disorder in a population-based sample of adults. Psychol Med 35:817–827.
  • Medori R, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemela A, Trott GE, et al. 2008. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 63:981–989.
  • Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, et al. 2001. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107:E105.
  • Pharmaceuticals and Medical Devices Agency. 2012. [in Japanese]. Available at: http://www.info.pmda.go.jp/shinyaku/P201200114/53047100_22100AMX00644_A100_1.pdf.
  • Takahashi M, Takita Y, Goto T, Ichikawa H, Saito K, Matsumoto H, et al. 2011a. An open-label, dose-titration tolerability study of atomoxetine hydrochloride in Japanese adults with attention-deficit/hyperactivity disorder. Psychiatry Clin Neurosci 65:55–63.
  • Takahashi M, Takita Y, Ichikawa H, Enomoto T, Okada T, Saito K, et al. 2011b. Reliability and Validity of the Japanese Version of CAARS-Screening Version (CAARS-SV), Adult ADHD Symptom Rating Scale [in Japanese]. Seishin Igaku 53:23–34.
  • Takeda T. 2009. Psychopharmacology for attention-deficit/hyperactivity disorder in Japan. Curr Attention Dis Rep 1:21–28.
  • Wilens TE, Morrison NR, Prince J. 2011. An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults. Expert Rev Neurother 11:1443–1465.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.